Gen Surg Vivas · surgical-critical-care
Damage control resuscitation in the bleeding trauma patient — ratio, clock, calcium, whole blood and limits
Fellowship viva on damage control resuscitation: ABC activation, PROPPR ratios with Bayesian reanalyses, TXA timing gradient with 90-minute refinement, calcium check-and-replace, neutral whole-blood RCTs, targeted fibrinogen, ITACTIC limits, VTE timing and the TBI exception.
On this page
Study tools
Target exams
Write your answer
Saved on this device. No marking — you are the marker.
Examiner probes
- He is hypotensive with a positive FAST and 2 units running at 60 minutes. Activate or wait — with what score, what ratio, and what do you do when the score says no?[32][5]
- TXA — exact dose, the three timing bands with numbers, the 90-minute refinement, and what happens if you miss the window?[16][17][18]
- Calcium 0.97 with citrated products running — replace, ignore, or protocol-bolus? Defend with both directions of the evidence.[21]
- Whole blood or components at this pressure — and fibrinogen for everyone or for the low? Answer with the 2026 trials and CRYOSTAT-2.[12][13][28][29]
- Viscoelastic testing and permissive hypotension — superiority or adjunct, and what changes with a severe head injury?[25][3]
Model responses
1. Activate now — equal ratios fast, scored formally but never vetoed by the score. Hypotension with a positive FAST and blood running is DCR on physiology: score the four ABC variables (penetrating, FAST-positive, systolic 90 or less, pulse 120 or more) while transfusing equal amounts of red cells, plasma and platelets in the early empiric phase.[32][5] Run PROPPR-honest: no mortality difference at 24 hours or 30 days, fewer exsanguinations, more haemostasis, complications equal — with Bayesian reanalyses assigning 93% and 87% probability of 1:1:1 superiority at those endpoints, strongest in the first hours of bleeding.[5][6] And when the ABC totals 1 in a patient clearly bleeding, transfuse anyway: in PROPPR the score managed only 66.8% sensitivity with 37.0% specificity, and gestalt enrolled more than a third of the trial below threshold.[35]
2. TXA 1 g now — inside every window that matters. Give 1 g over 10 minutes then 1 g over 8 hours: CRASH-2 all-cause 14.5% versus 16.0% (RR 0.91), bleeding death 4.9% versus 5.7% (RR 0.85).[16] At 60 minutes he sits in the best gradient band — within 1 hour RR 0.68, 1 to 3 hours RR 0.79, after 3 hours harm RR 1.44 — and inside the PATCH 90-minute optimum (within aRR 0.64, beyond aRR 1.04).[17][18] Missing the window converts benefit toward harm, so the loading dose travels with the first blood, never after the scan or the operation.
3. Check-and-replace calcium — both papers, one practice. Ionised 0.97 meets the verified 1.0-or-less threshold: prehospital plasma pushed hypocalcaemia from 36% to 53% (adjusted RR 1.48), with severe lows predicting decreased survival and massive transfusion — so measure with every round and replace under citrate load.[21] But refuse the fixed-dose protocol claim: in 346 activations 83.2% were hypocalcaemic yet neither first calcium nor citrate-corrected dose touched mortality — the physiology demands vigilance, not a dosing algorithm, and no milligram figure leaves your mouth.[22]
4. Components by default, whole blood by logistics; fibrinogen targeted, never empiric. Two 2026 prehospital randomised trials were neutral — TOWAR 30-day 25.9% versus 20.5% (adjusted OR 1.24), English composite 48.7% versus 47.7% (RR 1.02) — with LTO-WB safety proven (survival 73 versus 74%, post-department products median 0 versus 3, reactions confined to components).[12][13] So choose whole blood where the chain is simplest and balanced components where the bank runs equality well — superiority belongs to neither.[12] Fibrinogen goes only to documented lows with bleeding: empiric 3-pool cryoprecipitate changed 28-day death not at all (25.3 versus 26.1%), while high achieved cryoprecipitate ratios halved adjusted 6-hour mortality (aOR 0.52) — target, never flood.[28][29]
5. VHA advises, hypotension individualises, the injured brain overrules both. Viscoelastic assays see fibrinolysis and fibrinogen failure that conventional tests miss, yet ITACTIC showed no outcome difference (67 versus 64% alive free of massive transfusion; 25 versus 28% dead) with undertreatment explaining more than assay failure — adjunct with honest limits, no cutoff quoted.[25] Permissive hypotension earns its place in hospital (death 6.3 versus 16.3%, blunt 24-hour aOR 0.17, fewer respiratory and organ-failure complications) but not prehospital and never in brain injury.[3] With a severe head injury: normal pressure targets for the brain, TXA by the coma-scale rule (within 2 hours or GCS below 9, benefit possibly persisting), calcium and ratios unchanged — the brain sets the pressure, the clock still sets the drug.[19]
References17ShowHide
- [47]Lamb CM, MacGoey P, Navarro AP, et al. Damage control surgery in the era of damage control resuscitation. Br J Anaesth, 2014.PMID 25038156
- [32]Nunez TC, Voskresensky IV, Dossett LA, et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma, 2009.PMID 19204506
- [5]Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, 2015.PMID 25647203
- [6]Lammers D, Richman J, Holcomb JB, et al. Use of Bayesian Statistics to Reanalyze Data From the Pragmatic Randomized Optimal Platelet and Plasma Ratios Trial. JAMA Netw Open, 2023.PMID 36811858
- [16]Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010.PMID 20554319
- [17]Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet, 2011.PMID 21439633
- [18]Ali A, Gruen RL, Bernard SA, et al. Tranexamic Acid Timing and Mortality Impact After Trauma. Ann Emerg Med, 2026.PMID 40751727
- [19]Osawa I, Goto T, Roberts I Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials. Br J Surg, 2025.PMID 40277024
- [12]Sperry JL, Guyette FX, Cotton BA, et al. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. N Engl J Med, 2026.PMID 42150044
- [13]Smith JE, Cardigan R, Sanderson E, et al. Prehospital Whole Blood in Traumatic Hemorrhage - A Randomized Controlled Trial. N Engl J Med, 2026.PMID 41841706
- [21]Moore HB, Tessmer MT, Moore EE, et al. Forgot calcium? Admission ionized-calcium in two civilian randomized controlled trials of prehospital plasma for traumatic hemorrhagic shock. J Trauma Acute Care Surg, 2020.PMID 32317575
- [22]Chanthima P, Yuwapattanawong K, Thamjamrassri T, et al. Association Between Ionized Calcium Concentrations During Hemostatic Transfusion and Calcium Treatment With Mortality in Major Trauma. Anesth Analg, 2021.PMID 33646983
- [28]Davenport R, Curry N, Fox EE, et al. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA, 2023.PMID 37824155
- [29]Hynes AM, Cannon JW, Yan R, et al. Do not forget the cryoprecipitate: The impact of the 2019 Joint Trauma System Damage Control Resuscitation Clinical Practice Guideline on mortality. J Trauma Acute Care Surg, 2026.PMID 41589734
- [25]Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med, 2021.PMID 33048195
- [3]Indorewala Y, Nasef Y, Jayagopi K, et al. Permissive hypotension in adult trauma: A systematic review of outcomes across clinical settings, injury type, and resuscitation strategies. Am J Emerg Med, 2026.PMID 42030689
- [35]Baird EW, Lammers DT, Abraham P, et al. Diagnostic performance of the ABC score in the PROPPR trial. Injury, 2024.PMID 38852527